tiprankstipranks
DLH Holdings (DLHC)
NASDAQ:DLHC
US Market
Want to see DLHC full AI Analyst Report?

DLH Holdings (DLHC) Earnings Dates, Call Summary & Reports

105 Followers

Earnings Data

Report Date
Aug 05, 2026
Before Open (Confirmed)
Period Ending
2026 (Q3)
Consensus EPS Forecast
-0.17
Last Year’s EPS
0.02
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q2 2026
Earnings Call Date:May 06, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call communicated a mixed picture: material near-term financial headwinds with a steep year-over-year revenue decline (~33.5%) and a sharp drop in adjusted EBITDA (~43.6%), largely driven by program transitions to small business set-asides and contract completions. Offsetting these negatives, management reported margin resilience (9% adjusted EBITDA margin), positive free cash flow (~$3.8M), resumed deleveraging (debt reduced to $132.7M), a two-year NIH contract extension adding revenue visibility, recognition for technology capabilities, and an improving pipeline as delayed procurements return to market. Risks remain around federal health reprioritization and typical government procurement timing uncertainty, but the company appears to be stabilizing its cost structure and positioning for upcoming opportunities.
Company Guidance
The company guided that fiscal 2026 Q2 results reflected revenue of $59.3 million (vs. $89.2M year-ago), adjusted EBITDA of $5.3 million (vs. $9.4M), and an adjusted EBITDA margin of 9%, with roughly $3.8 million of free cash flow generated in the quarter; total debt was reduced to $132.7 million from $136.6 million the prior quarter (a $3.9M decline), and management expects to convert approximately 50%–55% of fiscal‑2026 EBITDA to debt reduction by year‑end while remaining in compliance with covenants; operationally they expect to complete the VA CMOP transition just before Memorial Day, received a two‑year sole‑source NIH extension, see a healthy pipeline with awards expected in the coming months (and some decisions by fiscal year‑end), and noted that FY2026 funding rose vs FY2025 for key federal health agencies while the President’s FY2027 request calls for historic defense/intel increases and unspecified federal health reductions.
Adjusted EBITDA Margin Maintained
Delivered adjusted EBITDA of $5.3 million and an adjusted EBITDA margin of 9% for the quarter, demonstrating margin resilience despite lower revenue.
Positive Free Cash Flow
Generated approximately $3.8 million of free cash flow in the quarter, supporting liquidity and deleveraging efforts.
Debt Reduction and Deleveraging Resumed
Total debt reduced to $132.7 million from $136.6 million the prior quarter (a reduction of ~$3.9 million, ~2.9%), with management expecting to convert ~50%–55% of fiscal 2026 EBITDA toward debt reduction by year-end and remaining in compliance with financial covenants.
Two-Year NIH Sole-Source Extension
Awarded a two-year sole-source extension to continue providing clinical research support services to the National Institutes of Health, adding short-term revenue visibility in the public health portfolio.
Improving Federal Funding Environment and Pipeline
Management highlighted that FY2026 budget outcomes and FY2027 requests show increased funding for defense/intelligence and some federal health agencies, improved procurement clarity, accelerating solicitations, and a healthy pipeline with multiple delayed procurements now coming to bid.
Recognition for Technology and Program Performance
Recent industry and customer recognitions for projects in automation, AI, scientific research, data science, and IT underline DLH's technical capabilities and differentiators (Cyclone, Nexus Labs digital sandbox).
Operational Right-Sizing Completed
Company implemented cost-scaling and right-sizing initiatives in Q2; management indicates the material reductions needed to align cost structure with near-term revenue have been achieved, with ongoing evaluation of leases and footprint.

DLH Holdings (DLHC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

DLHC Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 05, 2026
2026 (Q3)
-0.17 / -
0.02
May 06, 2026
2026 (Q2)
-0.16 / -0.17
0.06-383.33% (-0.23)
Feb 09, 2026
2026 (Q1)
-0.07 / -0.09
0.08-212.50% (-0.17)
Dec 10, 2025
2025 (Q4)
0.02 / -0.06
0.16-137.50% (-0.22)
Aug 06, 2025
2025 (Q3)
0.02 / 0.02
0.08-75.00% (-0.06)
May 07, 2025
2025 (Q2)
0.07 / 0.06
0.12-50.00% (-0.06)
Feb 05, 2025
2025 (Q1)
0.07 / 0.08
0.15-46.67% (-0.07)
Dec 04, 2024
2024 (Q4)
0.11 / 0.16
0.160.00% (0.00)
Jul 31, 2024
2024 (Q3)
0.14 / 0.08
0.12-33.33% (-0.04)
May 01, 2024
2024 (Q2)
0.13 / 0.12
0.06100.00% (+0.06)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

DLHC Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 06, 2026
$5.60$5.73+2.32%
Feb 09, 2026
$5.84$5.56-4.79%
Dec 10, 2025
$5.87$5.67-3.41%
Aug 06, 2025
$5.56$5.55-0.18%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does DLH Holdings (DLHC) report earnings?
DLH Holdings (DLHC) is schdueled to report earning on Aug 05, 2026, Before Open (Confirmed).
    What is DLH Holdings (DLHC) earnings time?
    DLH Holdings (DLHC) earnings time is at Aug 05, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is DLHC EPS forecast?
          DLHC EPS forecast for the fiscal quarter 2026 (Q3) is -0.17.